Hematological Oncology最新文献

{"title":"Different Epidemiology of Invasive Pulmonary Aspergillosis in Acute Lymphoblastic Leukemia in Comparison With Acute Myeloid Leukemia: Results of a Prospective Multicentric Observational Study of the Rete Ematologica Lombarda","authors":"C. Cattaneo,&nbsp;M. Bernardi,&nbsp;N. Fracchiolla,&nbsp;C. Pagani,&nbsp;F. Gigli,&nbsp;C. Basilico,&nbsp;L. Masina,&nbsp;E. Borlenghi,&nbsp;A. Bruno,&nbsp;G. Gela,&nbsp;G. Rossi,&nbsp;A. Tucci,&nbsp;D. Bertoli,&nbsp;F. Lussana,&nbsp;E. Todisco","doi":"10.1002/hon.70045","DOIUrl":"https://doi.org/10.1002/hon.70045","url":null,"abstract":"<div>\u0000 \u0000 <p>The negative impact of invasive pulmonary aspergillosis (IPA) in acute myeloid leukemia (AML) is well known whereas its clinical relevance in acute lymphoid leukemia (ALL) is still unclear. We have carried out a prospective multicentric observational study within the Rete Ematologica Lombarda to describe the incidence of IPA in acute leukemia (AL) patients, focusing on differences between AML and ALL. Between 2018 and 2020, 207 AL patients (AML: 165, ALL: 42) were evaluated. During induction, proven/probable and possible IPA were diagnosed in 32/207 patients (15.4%), equally divided into proven/probable and possible (16 each, 7.7%). IPA diagnosis was made in 23/165 (13.9%) AML and in 9/42 (21.4%) ALL patients (<i>p</i> = 0.2374). Proven/probable IPA were more frequent in ALL than in AML (ALL: 7/42, 16.6% vs. AML: 9/165, 5.4%; <i>p</i> = 0.0235). OS was similar in patients with or without proven/probable IPA (not reached vs. 63 months, <i>p</i> = 0.588), while OS was significantly reduced in possible IPA (22 months vs. not reached, <i>p</i> = 0.0167). More than 15 days of neutropenia duration and lack of antimold prophylaxis were associated with IPA. Achieving complete remission was protective, whereas age over 60 years and, with a borderline significance, possible IPA were associated with risk of death. In conclusion, Ph-negative ALL should be considered at the same high risk for IPA as AML. Antimold prophylaxis should be probably extended also to ALL.</p>\u0000 </div>","PeriodicalId":12882,"journal":{"name":"Hematological Oncology","volume":"43 2","pages":""},"PeriodicalIF":3.3,"publicationDate":"2025-02-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143396955","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Direct-Acting Antivirals Induce Lymphoproliferative Disease Response in HCV-Infected Patients With Indolent B-Cell Non-Hodgkin’s Lymphoma: A Prospective Observational Study","authors":"Monica George,&nbsp;Khalis Mustafayev,&nbsp;Sairah Ahmed,&nbsp;Sheeba K. Thomas,&nbsp;Ying Jiang,&nbsp;Krina Patel,&nbsp;Harrys A. Torres","doi":"10.1002/hon.70044","DOIUrl":"https://doi.org/10.1002/hon.70044","url":null,"abstract":"<div>\u0000 \u0000 <p>B-cell non-Hodgkin lymphoma (NHL) in one of the most serious extrahepatic manifestations of chronic hepatitis C virus (HCV) infection. No prospective studies have been conducted in the United States (US) on the impact of direct-acting antivirals (DAAs) in HCV-infected patients with indolent B-cell NHL not requiring chemotherapy. In this prospective study, we evaluated the general characteristics of US patients with HCV-associated indolent B-cell NHL and the oncologic impact of only DAA treatment without systemic cancer therapy in those patients. We enrolled patients seen at our center during 2014–2021; we analyzed only chemotherapy-naïve patients treated with DAAs. Patients who required immediate conventional treatment for lymphoma were excluded from the study. The primary endpoints were sustained virologic response at 12 weeks (SVR12) and lymphoproliferative disease response, classified as complete response, partial response, stable disease, or progressive disease. The secondary endpoints were overall response rate (ORR) of NHL, duration of response (DOR), overall survival (OS), and progression-free survival (PFS). Nine patients met the study criteria and were analyzed. Most patients were male (<i>n</i> = 6), White (<i>n</i> = 6), younger than 65 years (<i>n</i> = 6), and non-cirrhotic (<i>n</i> = 8); had HCV genotype 1 (<i>n</i> = 5); and had been infected for more than 30 years (<i>n</i> = 7). All patients achieved SVR12. Six patients (67%) had complete response, and 3 (33%) had progressive disease. The ORR was 67%. The median DOR was 51 months (range 16–81 months). The 5-year DOR, OS, and PFS rates were 100%, 83%, and 67%, respectively. HCV-associated NHL is a late extrahepatic complication of HCV. Infected patients with indolent NHL have an excellent virologic responses to DAAs and most of them experienced a favorable oncologic response after HCV eradication without chemotherapy.</p>\u0000 </div>","PeriodicalId":12882,"journal":{"name":"Hematological Oncology","volume":"43 2","pages":""},"PeriodicalIF":3.3,"publicationDate":"2025-02-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143370091","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Early Detection and Central Nervous System Prophylaxis in Patients With High-Risk Features of Primary Lymphoma of the Female Genital Tract: The Key to Improved Prognosis","authors":"Bingyi Wang,&nbsp;Yaxiao Lu,&nbsp;Jing Zhao,&nbsp;Lanfang Li,&nbsp;Lihua Qiu,&nbsp;Zhengzi Qian,&nbsp;Shiyong Zhou,&nbsp;Xianhuo Wang,&nbsp;Huilai Zhang","doi":"10.1002/hon.70035","DOIUrl":"https://doi.org/10.1002/hon.70035","url":null,"abstract":"<div>\u0000 \u0000 <p>Primary lymphoma of the female genital tract (PLFGT) is a rare disease. The incidence is gradually increasing each year. There have been few reports about PLFGT, and most of them have involved individual cases and small-sample retrospective analyses. The pathogenesis of PLFGT is still under exploration and may be associated with hormones, inflammation/infection, and immunodeficiency. Diffuse large B-cell lymphoma (DLBCL) is the most common pathological type. The majority of the patients presented with vaginal bleeding, abdominal pain, an abdominal mass, and other nonspecific symptoms. Lymphoma-associated B symptoms are quite rare. These patients initially visited gynecological departments, possibly leading to misdiagnosis due to nonspecific features. The treatment strategies for and prognosis of PLFGT differ substantially from those of other gynecologic malignancies. Thus, interdisciplinary cooperation among gynecologists, pathologists, and hematologists is essential.</p>\u0000 </div>","PeriodicalId":12882,"journal":{"name":"Hematological Oncology","volume":"43 2","pages":""},"PeriodicalIF":3.3,"publicationDate":"2025-02-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143248792","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Moderate-To-Severe Bone Marrow Fibrosis Is an Independent Risk Factor For Myelodysplastic Neoplasms Patients With Increased Blasts","authors":"Gaixiang Xu,&nbsp;Xingnong Ye,&nbsp;Yudi Zhang,&nbsp;Wei Wang,&nbsp;Shuanghong Zhu,&nbsp;Kongfei Li,&nbsp;Xinping Zhou,&nbsp;Liya Ma,&nbsp;Li Ye,&nbsp;Chen Mei,&nbsp;Lu Wang,&nbsp;Yanling Ren,&nbsp;Lingxu Jiang,&nbsp;Jian Huang,&nbsp;Haitao Meng,&nbsp;Wenyuan Mai,&nbsp;Wenjuan Yu,&nbsp;Jie Jin,&nbsp;Hongyan Tong","doi":"10.1002/hon.70043","DOIUrl":"10.1002/hon.70043","url":null,"abstract":"<div>\u0000 \u0000 <p>This study, including 412 patients newly diagnosed with myelodysplastic neoplasm (MDS), investigated the clinical, molecular, and prognostic features of MDS with moderate-to-severe bone marrow fibrosis (MF). Among the patients with MDS, 347 (84%) had MF grade 0–1 (MF0–1), and 65 (16%) had MF grade 2–3 (MF2–3). Patients with MDS with MF2–3 showed similar overall survival (OS) (16.6 vs. 21.3 months; <i>p</i> = 0.34) but demonstrated inferior progression-free survival (PFS) (6.6 vs. 15.2 months; <i>p</i> = 0.02) and a higher risk of leukemia transformation (35.4 vs. 16.4%; <i>p</i> &lt; 0.001) compared to those with MF0–1. In the MDS with excess blast (MDS-EB) subtypes, individuals with MF2-3 exhibited shorter OS (4.8 vs. 11.7 months; <i>p</i> = 0.01) and PFS (3.1 vs. 7.9 months; <i>p</i> = 0.006) than those in patients with MF0-1. However, individuals with MF0-1 and MF2-3 showed similar OS and PFS rates among the patients with the MDS non-excess blast (MDS-nonEB) subtypes. Additionally, we reclassified the patients with MDS according to the 2022 World Health Organization (WHO) classification. Patients with MDS with fibrosis (MDS-f) had a shorter OS (5.6 vs. 13.8 months; <i>p</i> = 0.01) and PFS (3.1 vs. 7.9 months; <i>p</i> = 0.006) than MDS with increased blasts (MDS-IB) subtypes. Our study reveals the unique features of patients with MDS-MF2-3 and validates the refinements made in the 5th edition of the WHO proposal.</p>\u0000 </div>","PeriodicalId":12882,"journal":{"name":"Hematological Oncology","volume":"43 2","pages":""},"PeriodicalIF":3.3,"publicationDate":"2025-02-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143079462","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy and Prognostic Indicators of Isatuximab, Pomalidomide, and Dexamethasone (IsaPd) in Daratumumab-Refractory Multiple Myeloma Patients: A Multicenter Real-World Study","authors":"Enrica Antonia Martino,&nbsp;Daniele Derudas,&nbsp;Elena Rossi,&nbsp;Paola Stefanoni,&nbsp;Silvia Mangiacavalli,&nbsp;Elena Zamagni,&nbsp;Massimo Offidani,&nbsp;Anna Furlan,&nbsp;Angela Maria Quinto,&nbsp;Roberta Della Pepa,&nbsp;Giuseppe Bertuglia,&nbsp;Emiliano Barbieri,&nbsp;Concetta Conticello,&nbsp;Claudio De Magistris,&nbsp;Velia Bongarzoni,&nbsp;Anna Maria Cafro,&nbsp;Anna Mele,&nbsp;Cirino Botta,&nbsp;Nicola Sgherza,&nbsp;Giuseppe Mele,&nbsp;Ombretta Annibali,&nbsp;Angela Rago,&nbsp;Raffaele Fontana,&nbsp;Ernesto Vigna,&nbsp;Antonella Bruzzese,&nbsp;Katia Mancuso,&nbsp;Angela Amendola,&nbsp;Annalisa Citro,&nbsp;Emilia Cotzia,&nbsp;Sonia Morè,&nbsp;Elena Rivolti,&nbsp;Loredana Pettine,&nbsp;Monica Galli,&nbsp;Valerio De Stefano,&nbsp;Maria Teresa Petrucci,&nbsp;Alessandro Corso,&nbsp;Antonino Neri,&nbsp;Francesco Di Raimondo,&nbsp;Niccolò Bolli,&nbsp;Pellegrino Musto,&nbsp;Fortunato Morabito,&nbsp;Massimo Gentile","doi":"10.1002/hon.70042","DOIUrl":"10.1002/hon.70042","url":null,"abstract":"<p>This multicenter real-world analysis evaluated the efficacy of isatuximab, pomalidomide, and dexamethasone (IsaPd) in 51 patients with multiple myeloma (MM) who were refractory to daratumumab (Dara-R). The majority were under 70 years old (60.8%), predominantly female (56.9%), and heavily pretreated, with 74.5% being triple-class refractory (TCR); 32.1% of the 28 patients with cytogenetic data had high-risk abnormalities. The overall response rate (ORR) was 56.9%, including 3 patients with stringent complete response (sCR), 4 with CR, and 7 with very good partial response (VGPR). Neither age, number of prior therapies, TCR status, nor time from Dara refractoriness to IsaPd initiation significantly affected response rates.</p><p>Median progression-free survival (PFS) was 5.8 months, with a 12-month PFS probability of 30.6%. Baseline hemoglobin (Hb) levels were a key predictor of PFS: patients with Hb &lt; 11.8 g/L had a 3.5-fold increased risk of progression, with a median PFS of 4.6 months compared to 22 months in those with higher Hb.</p><p>Median overall survival (OS) was 21.0 months, with a 12-month OS probability of 63.4%. Lower Hb levels (&lt; 11 g/L) were associated with a tenfold increased risk of mortality.</p><p>Among the 28 patients who underwent FISH analysis, while no significant difference in mortality risk was observed, those with high-risk cytogenetic abnormalities exhibited a nearly tenfold increased risk of disease progression.</p><p>These results suggest that IsaPd offers a meaningful option for Dara-R patients, with Hb levels serving as a critical predictor of both PFS and OS. However, PFS remains modest, underscoring the need for novel combination therapies.</p>","PeriodicalId":12882,"journal":{"name":"Hematological Oncology","volume":"43 2","pages":""},"PeriodicalIF":3.3,"publicationDate":"2025-02-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/hon.70042","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143079460","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparative Safety of Ibrutinib Versus Zanubrutinib in Patients With Chronic Lymphocytic Leukemia: A Prospective Cohort Study","authors":"Fuli Fan,&nbsp;Xiaodan Liu,&nbsp;Zhan Su,&nbsp;Saisai Li,&nbsp;Chuanlei Wang,&nbsp;Shibo Wang,&nbsp;Shuxia Cui,&nbsp;Yuting Yan","doi":"10.1002/hon.70041","DOIUrl":"10.1002/hon.70041","url":null,"abstract":"<div>\u0000 \u0000 <p>This study compares the safety profiles of two Bruton's tyrosine kinase (BTK) inhibitors, Ibrutinib and Zanubrutinib, in patients with chronic lymphocytic leukemia (CLL). While Ibrutinib has transformed CLL treatment, it is associated with significant adverse events (AEs). Zanubrutinib, a second-generation BTK inhibitor, offers potential for improved safety. In this prospective study, 200 CLL patients were enrolled, with 100 receiving Ibrutinib and 100 receiving Zanubrutinib. Baseline characteristics such as age, sex, body mass index (BMI), Eastern Cooperative Oncology Group (ECOG) performance status, and genetic factors were evaluated. AEs and serious AEs (SAEs) were tracked and graded using the Common Terminology Criteria for Adverse Events (CTCAE). Multivariate logistic regression models were conducted to determine predictors of SAE and AEs grade ≥ 3. Adjusted odds ratio (aOR) and 95% confidence interval (CI) were reported. The mean ages of the Ibrutinib and Zanubrutinib groups were 49.65 and 49.16 years, respectively (<i>p</i> = 0.285). The Zanubrutinib group had a higher percentage of patients with worse ECOG status (71% vs. 57%, <i>p</i> = 0.039). Fewer Zanubrutinib patients experienced severe AEs (4% vs. 9%, <i>p</i> = 0.152) or SAEs (8% vs. 17%, <i>p</i> = 0.054). Neutropenia occurred only in the Ibrutinib group (3%). Subgroup analysis showed a higher complication rate with Zanubrutinib in non-refractory patients (11.40% vs. 5.26%, <i>p</i> = 0.065). Stage III CLL was a protective factor of grade ≥ 3 AEs (aOR = 0.007; 95% CI: 0.0003–0.1829) and SAE (aOR = 0.015; 95% CI: 0.001–0.177). While ECOS status (2 vs. 3) resulted in reduced risk of SAE, chromosome 17p deletion emerged as the main risk factor of SAE (aOR = 6.40; 95% CI: 1.33–30.79). Zanubrutinib demonstrated a more favorable safety profile than Ibrutinib, with fewer severe adverse events. It may be a safer alternative for CLL patients, particularly those at higher risk for complications from BTK inhibitors. However, these differences stemmed from variability in baseline clinical characteristics rather than the interventions themselves.</p>\u0000 </div>","PeriodicalId":12882,"journal":{"name":"Hematological Oncology","volume":"43 2","pages":""},"PeriodicalIF":3.3,"publicationDate":"2025-01-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143065188","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comprehensive Characterization of Overt Myelofibrosis in an Asian Cohort: Phenotype, Mutation Landscape and Discordance Among Scoring Systems","authors":"Yu-Sung Chang,&nbsp;Yu-Hung Wang,&nbsp;Chao-Hung Wei,&nbsp;Yu-Wen Chen,&nbsp;Hsing-Yu Lin,&nbsp;Chien-Chin Lin,&nbsp;Xavier Cheng-Hong Tsai,&nbsp;Chang-Tsu Yuan,&nbsp;Feng-Ming Tien,&nbsp;Yun-Chu Lin,&nbsp;Sze-Hwei Lee,&nbsp;Yuan-Yeh Kuo,&nbsp;Ming-Kai Chuang,&nbsp;Bor-Sheng Ko,&nbsp;Ming Yao,&nbsp;Hwei-Fang Tien,&nbsp;Wen-Chien Chou,&nbsp;Hsin-An Hou","doi":"10.1002/hon.70040","DOIUrl":"10.1002/hon.70040","url":null,"abstract":"<div>\u0000 \u0000 <p>Various prognostic scoring systems in myelofibrosis (MF) have been developed to guide clinical decision-making in MF. However, discrepancies between different scoring systems for individual patients remain poorly understood, which can result in conflicting treatment recommendations. Moreover, data regarding there applicability in Asian populations remain scarce. We conducted a retrospective analysis of patients with overt MF at National Taiwan University Hospital from November 1, 2006, to November 30, 2023. This study evaluates the distribution, concordance, and prognostic value of various scoring systems (IPSS, DIPSS, DIPSS+, MYSEC-PM, MIPSS70, MIPSS70+v2, GIPSS), focusing on the mutational landscape, particularly <i>TP53</i> mutations, and cytopenic phenotypes in an Asian MF cohort. All prognostic systems effectively stratified patients by risk (<i>p</i> &lt; 0.005); however, concordance between systems was low (Cohen's <i>κ</i> &lt; 0.4, except for IPSS <i>vs</i>. DIPSS+). GIPSS demonstrated superior performance with a comparable C-index but lower Akaike and Bayesian information criterion values. Besides high-molecular risk mutations, <i>TP53</i> mutations (5.2%) were associated with worse overall survival (OS) (5-year: 30% <i>vs</i>. 68%, <i>p</i> &lt; 0.001) and a trend toward higher leukemic transformation (5-year: 22% <i>vs</i>. 10%, <i>p</i> = 0.055). Cytopenic phenotype (59%) was associated with a higher incidence of <i>ASXL1</i> mutations (44% <i>vs</i>. 28%, <i>p</i> = 0.04). In multivariable analysis, elderly patients, higher-risk GIPSS, <i>TP53</i> mutation and cytopenic phenotype were associated with a poorer OS. This study validated multiple prognostic scoring systems in an Asian MF cohort, with GIPSS showing superior risk stratification. Further, cytopenic phenotype and <i>TP53</i> mutations were identified as independent factors linked to poorer survival.</p>\u0000 </div>","PeriodicalId":12882,"journal":{"name":"Hematological Oncology","volume":"43 1","pages":""},"PeriodicalIF":3.3,"publicationDate":"2025-01-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143033084","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correction to Elotuzumab Plus Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Extended Follow-Up of a Multicenter, Retrospective Real-World Experience With 321 Cases Outside of Controlled Clinical Trials","authors":"","doi":"10.1002/hon.70039","DOIUrl":"10.1002/hon.70039","url":null,"abstract":"<p>Martino EA, Palmieri S, Galli M, et al. Elotuzumab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended follow-up of a multicenter, retrospective real-world experience with 321 cases outside of controlled clinical trials. <i>Hematol Oncol</i>. 2024;42(4):e3290. https://doi.org/10.1002/hon.3290</p><p>In the article, affiliation 42 for author Barbara Gamberi is not correct. The correct affiliation for Dr. Barbara Gamberi is “Hematology Unit, Azienda Unità Sanitaria Locale – IRCCS of Reggio Emilia, Reggio Emilia, Italy”.</p><p>We apologize for this error.</p>","PeriodicalId":12882,"journal":{"name":"Hematological Oncology","volume":"43 1","pages":""},"PeriodicalIF":3.3,"publicationDate":"2025-01-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/hon.70039","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143023212","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of Recent Translational and Therapeutic Developments on Clinical Course of BCR::ABL1-Positive and -Negative Myeloproliferative Neoplasms","authors":"Tariq I. Mughal,&nbsp;John Mascarenhas,&nbsp;Raajit K. Rampal,&nbsp;Prithviraj Bose,&nbsp;Thomas Lion,&nbsp;Helen Ajufo,&nbsp;Abdulraheem Yacoub,&nbsp;Soheil Meshinchi,&nbsp;Lucia Masarova,&nbsp;Ruben Mesa,&nbsp;Catriona Jamieson,&nbsp;Tiziano Barbui,&nbsp;Giuseppe Saglio,&nbsp;Richard A. Van Etten","doi":"10.1002/hon.70013","DOIUrl":"10.1002/hon.70013","url":null,"abstract":"<div>\u0000 \u0000 <p>Despite the study of <i>BCR::ABL1</i>-positive and -negative myeloproliferative neoplasms (MPNs) providing seminal insights into cancer biology, tumor evolution and precision oncology over the past half century, significant challenges remain. MPNs are clonal hematopoietic stem cell-derived neoplasms with heterogenous clinical phenotypes and a clonal architecture which impacts the often-complex underlying genetics and microenvironment. The major driving molecular abnormalities have been well characterized, but debate on their role as disease-initiating molecular lesions continues. The introduction of the ABL1 tyrosine kinase inhibitors have been extremely successful in the treatment of chronic myeloid leukemia with most patients having a near-normal life expectancy. Similar success has, however, not been achieved for <i>BCR::ABL1</i>-negative MPNs in terms of disease course modification and most patients remain incurable. In both disease categories, genomic instability seems to increase the risk of disease progression to accelerated/blast phase, which is resistant/refractory to conventional treatment and associated with a poor prognosis. To address some of these issues, the late John Goldman and Tariq Mughal founded a scientific and clinical platform in 2006, the Post-American Society of Hematology (ASH) MPN workshop, to appraise novel cancer biology, candidate therapeutic targets, treatments and other clinical challenges and pay tribute to all the many scientists and clinicians around the world instrumental to the progress made and continuing advances being made. This paper summarizes some of the recent data discussed at the 18^th edition of the workshop and includes reference to some data presented or published after the workshop, including the 26^th John Goldman CML conference.</p>\u0000 </div>","PeriodicalId":12882,"journal":{"name":"Hematological Oncology","volume":"43 1","pages":""},"PeriodicalIF":3.3,"publicationDate":"2025-01-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143004409","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Successful Pregnancies During Crizotinib Therapy for Anaplastic Lymphoma Kinase Positive Lymphoma","authors":"Veronica Guglielmana,&nbsp;Francesco Maria Fusi,&nbsp;Valentina Giardini,&nbsp;Federica Cocito,&nbsp;Carlo Gambacorti-Passerini","doi":"10.1002/hon.70038","DOIUrl":"10.1002/hon.70038","url":null,"abstract":"<p>Anaplastic lymphoma kinase positive (ALK+) anaplastic large cell lymphoma (ALCL) typically affects young individuals and, despite high responsiveness to cytotoxic drugs, relapses occur in over 50% of patients. Crizotinib has improved outcomes, but its management in patients desiring parenthood remains an issue. This study presents the first description of four successful pregnancies during crizotinib treatment for ALK+ALCL: a female patient achieving two pregnancies through assisted reproductive technologies (ART), temporarily discontinuing crizotinib and maintaining a complete remission (CR), and a male patient conceiving naturally while on continuous therapy. These cases demonstrate crizotinib potential to support conception without compromising disease control, even in the absence of specific guidelines on treatment discontinuation.</p>","PeriodicalId":12882,"journal":{"name":"Hematological Oncology","volume":"43 1","pages":""},"PeriodicalIF":3.3,"publicationDate":"2025-01-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11732784/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142983299","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}